Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies

被引：0
|
作者：
Fanale, Michelle [1 ]
Bensinger, William I. [2 ]
Byrd, John C. [3 ]
Ewald, Brett [4 ]
Carreon, Daniel [4 ]
Baeck, Johan [4 ]
Freedman, Arnold S. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, Clin Div, Seattle, WA 98104 USA
[3] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1581 / 1581
页数：1
相关论文
共 49 条
  • [1] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
    Byrd, John C.
    Kipps, Thomas J.
    Flinn, Ian W.
    Cooper, Maureen
    Odenike, Olatoyosi
    Bendiske, Jennifer
    Rediske, John
    Bilic, Sanela
    Dey, Jyotirmoy
    Baeck, Johan
    O'Brien, Susan
    LEUKEMIA & LYMPHOMA, 2012, 53 (11) : 2136 - 2142
  • [2] hCD122, an antagonist human Anti-CD40 monoclonal antibody, enhances efficacy of CHOP in tumor xenograft model of human diffuse large B-Cell lymphoma.
    Luqman, Mohammad
    Hsu, Ssucheng J.
    Ericson, Matthew
    Klabunde, Sha
    Kantak, Seema
    BLOOD, 2007, 110 (11) : 162A - 162A
  • [3] A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
    Bensinger, William
    Maziarz, Richard T.
    Jagannath, Sundar
    Spencer, Andrew
    Durrant, Simon
    Becker, Pamela S.
    Ewald, Brett
    Bilic, Sanela
    Rediske, John
    Baeck, Johan
    Stadtmauer, Edward A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) : 58 - 66
  • [4] A phase I dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma.
    Bensinger, William
    Jagannath, Sundar
    Becker, Pamela S.
    Anderson, Kenneth C.
    Stadtmauer, Edward A.
    Aukerman, Lea
    Fox, Judith
    Girish, Sandhva
    Bilic, Sanela
    Guzy, Serge
    Solinger, Alan
    Dort, Sherri
    Wang, Yongyu
    Hurst, Deborah
    BLOOD, 2006, 108 (11) : 1021A - 1021A
  • [5] HCD122, an antagonist human anti-CD40 monoclonal antibody, inhibits tumor growth in xenograft models of human diffuse large B-Cell lymphoma, a subset of non-hodgkins lymphoma.
    Hsu, Ssucheng J.
    Esposito, Lin A.
    Aukerman, Sharon L.
    Kantak, Seema
    Mirza, Amer M.
    BLOOD, 2006, 108 (11) : 713A - 713A
  • [6] Efficacy of an antagonistic Anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human Non-Hodgkin's lymphoma and Hodgkin's disease.
    Long, Li
    Patawaran, Montesa
    Tong, Xia
    Kantak, Seema
    Aukerman, Sharon L.
    Pryer, Nancy
    Luqman, Mohammad
    BLOOD, 2006, 108 (11) : 72A - 72A
  • [7] Pharmaco kinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia.
    Byrd, John C.
    Flinn, Ian W.
    Khan, Khuda D.
    Kipps, Thomas J.
    Aukerman, Lea
    Fox, Judith
    Girish, Sandhya
    Guzy, Serge
    Bilic, Sanela
    Solinger, Alan
    Dort, Sherri
    Wang, Yongyu
    Hurst, Deborah
    O'Brien, Susan
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [8] Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
    Bornstein, Gadi Gazit
    Queva, Christophe
    Tabrizi, Mohammad
    van Abbema, Anne
    Chavez, Carlos
    Wang, Ping
    Foord, Orit
    Ahluwalia, Kiran
    Laing, Naomi
    Raja, Sandhya
    Wen, Shenghua
    Green, Larry L.
    Yang, Xiaodong
    Webster, Carl
    Stewart, Ross
    Blakey, David
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (05) : 561 - 574
  • [9] Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-Cell malignancies
    Bornstein, Gadi Gazit
    Queva, Christophe
    Tabrizi, Mohammad
    VanAbbema, Anne
    Chavez, Carlos
    Wang, Ping
    Laing, Naomi
    Raja, Sandhya
    Wen, Shenghua
    Rong, Xianhui
    Green, Larry L.
    Yang, Xiaodong
    Blakey, David
    BLOOD, 2007, 110 (11) : 694A - 695A
  • [10] Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
    Gadi Gazit Bornstein
    Christophe Quéva
    Mohammad Tabrizi
    Anne van Abbema
    Carlos Chavez
    Ping Wang
    Orit Foord
    Kiran Ahluwalia
    Naomi Laing
    Sandhya Raja
    Shenghua Wen
    Larry L. Green
    Xiaodong Yang
    Carl Webster
    Ross Stewart
    David Blakey
    Investigational New Drugs, 2010, 28 : 561 - 574
12345